We focus on the needs of medtech, biopharma and tech businesses

Andrew is an experienced commercial leader specialising in medtech, diagnostic and biopharma and now leads teams for Anexys Health supporting companies in these sectors.

He was the founder and CEO of ANGLE plc specialising in cancer diagnostics and led development of the Parsortix liquid biopsy system successfully securing a de novo US FDA clearance. Andrew raised over £140 million and built the company from start-up through to a listed valuation in excess of £400 million.

Andrew is Chairman of 4D Medicine (bioabsorbable medical implants for nerve repair) and Non Executive Director of Arenko (enterprise software for battery energy storage).

Previously Andrew built and led a specialist consulting business for IP commercialisation and the development and operation of business incubation programmes. He has founded and led spin-out companies from Dstl Porton Down (rapid MRSA diagnostics sold to 3M), Cambridge University (computer graphics sold to ARM), University of York (IVF technology sold to CooperSurgical), the Rowett Institute (nutraceuticals IPO) and British Telecom (knowledge management software sold to listed company).

Andrew has an MA in Engineering Science from the University of Cambridge and is a qualified chartered accountant. He has extensive corporate governance experience having led a UK publicly listed company for many years.

Anne-Sophie is a senior R&D and innovation leader specialising in oncology diagnostics, liquid biopsy, precision medicine and medical technologies. She has over 15 years of experience across translational research, technology development, clinical and analytical validation, regulatory evidence generation and R&D strategy.

She spent ten years at ANGLE plc, most recently as Senior Director and Head of R&D, where she built and led a multidisciplinary R&D organisation and a £10–15 million portfolio of technology and evidence-generation programmes. She played a key role in the development and regulatory validation of the Parsortix liquid biopsy system, supporting its successful US FDA De Novo clearance and European regulatory registration. Her work spanned early scientific development through human studies, analytical and clinical validation, regulatory submissions and publications.

Anne-Sophie has extensive experience working at the interface of science, technology, clinical development and business strategy. She has advised executive leadership and boards on R&D strategy, portfolio prioritisation, investment decisions, technology development and risk, and has led collaborations with pharmaceutical companies, clinical partners and key opinion leaders. Her technical experience includes cell-based and biomarker assays, circulating tumour cells, ctDNA, exosomes, NGS, multiplex imaging and molecular diagnostics.

She now works as an independent R&D and innovation advisor, supporting healthcare, diagnostics, medtech and biotechnology companies with scientific and technology strategy, R&D planning, evidence-generation programmes and the translation of innovative technologies towards clinical and commercial applications.

Anne-Sophie holds a Global MBA from Warwick Business School, graduating with Distinction and specialising in healthcare. She also has a scientific background in oncology and translational research.

Bill Standwill is a US-based commercial strategy and business development executive with over 20 years of experience in diagnostics, medical devices and life sciences. He specialises in helping international companies assess US market opportunities, develop market entry strategies and successfully launch and expand their businesses.

Bill has held senior commercial leadership roles at Danaher/Leica Biosystems, LabCorp/Dianon, Exact Sciences, Myriad Genetics and other innovative diagnostics companies. His expertise spans market assessment, commercial strategy, product positioning, pricing, reimbursement, strategic partnerships and go-to-market execution.

As founder of Standwill Consulting, Bill advises emerging and established companies on US commercialisation, growth strategy and business development, bringing practical operating experience and extensive knowledge of the US healthcare and diagnostics markets.

David is an experienced scientific and commercialisation leader specialising in oncology, translational medicine, and cross-sector partnering. He brings over 30 years of operating experience across biomedical research, technology transfer, executive organisational leadership, and multi-stakeholder consortium building.

Most recently, David led childhood cancer strategy at LifeArc, establishing its translational framework and founding C-Further, an international consortium dedicated to accelerating paediatric oncology drug discovery through multi-partner co-funding. He was also the convening force behind the Paediatric Therapeutic Development Workshop series published in the British Journal of Cancer. Previously, as Chief Scientific Officer and interim CEO of The Brain Tumour Charity, he led an organisation of 80 staff through post-pandemic recovery, transformed scientific funding to focus on translational impact, and established the charity as a pre-eminent international funder driving clinical trial acceleration and patient benefit.

Earlier, David spent over a decade at Cancer Research Technology directing technology assessment, IP protection, and commercial licensing. He pioneered innovative alliance models partnering academic drug discovery with global pharmaceutical companies, alongside securing commercial co-funding and orphan drug designations.

David is a General Assembly Member of ACCELERATE, advancing international paediatric drug development, and advises biopharma, non-profit organisations, and investors on translational roadmaps, scientific due diligence, and partnering strategies.

David holds a PhD in Molecular Cell Biology from the University of London and a Postgraduate Certificate in Leadership and Management from Roffey Park (University of Sussex).

Ghada is an experienced life sciences executive with over 20 years of international experience across molecular diagnostics, medical devices and biotechnology. She combines operational leadership with strong scientific, technical and commercial expertise, having held senior executive and commercial roles in multinational and publicly listed companies.

Most recently, Ghada served as Chief Operating Officer at ANGLE plc, where she led business operations, strategy and commercial readiness. She now advises life sciences and medical device companies on operational readiness, helping them identify gaps, strengthen capabilities and prepare for commercial growth.

Throughout her career, Ghada has led strategic initiatives spanning product development and commercialisation, international partnerships, market expansion and major pharmaceutical collaborations. Her experience includes negotiating complex commercial agreements, identifying new market opportunities, developing product value propositions and supporting regulatory clearance and product launches.

Ghada brings a practical and commercially focused approach to translating strategy into execution, helping businesses navigate operational complexity, strengthen performance and achieve sustainable growth.

She holds a PhD in Cancer Research and Experimental Medicine from Imperial College London and an MBA from Imperial Business School.

Ian is an experienced C-suite leader specialising for over 30 years in finance and business intelligence with a focus on medtech, diagnostic, biopharma and the broader technology space.

Ian was the Chief Financial Officer of ANGLE plc (AIM listed) which specialised in cancer diagnostics and developed the Parsortix liquid biopsy system successfully securing a de novo US FDA clearance and becoming a world-leading circulating tumour cell company. Ian played a key role in building the company from start-up through to a significant listed valuation when FDA De Novo clearance was secured and over some 20 years helped raise over £140 million. As well as leading the finance function and all that entails, Ian was in charge of Investor Relations and business intelligence.

Ian played a key role in developing the original specialist consulting business for IP commercialisation and the development and operation of business incubation programmes where he ran a number of initiatives and helped establish and develop businesses in the UK, US and the Middle East. Ian was also heavily involved in the start-up phase and ongoing development of ANGLE’s own ventures in the UK and US by working closely with management on business plans, financial and operational management, fundraising and commercial aspects.

Ian has an BSc in Mathematics with Management Applications from Brunel University and is a qualified chartered accountant. He worked for KPMG for seven years, initially in accountancy with a focus on special work, then in the High Technology management consulting Group.

With over three decades of experience in the pharmaceutical sector, Karen bridges the gap between breakthrough science and commercial success. As an independent strategic advisor, she helps biotech and medtech companies align research with financial goals, specialising in portfolio building and strategic realignment, corporate infrastructure, navigating regulatory landscapes, and scaling high-performing global teams.

Throughout her career, Karen has focused on transforming novel scientific concepts, including cell and gene therapies, advanced biological modalities, and therapeutic pipelines, into high-value assets and commercial partnerships.

Her experience spans the entire drug development lifecycle, from early discovery, new drug delivery concepts, medical devices, quality management and clinical biomarkers, through to clinical drug development and post-commercialisation activities.

As a seasoned C-suite executive, Karen is skilled at connecting boards, investors, and scientific teams to advance therapeutic pipelines and build large-scale partnerships. Her foundational expertise is rooted in a strong academic background, including a BSc in Medical Cell Biology and Biochemistry, an industry-sponsored PhD, and postdoctoral research at EMBL and Imperial College London.

Mark is a clinical research entrepreneur with more than 30 years’ experience across pharma, CROs and specialist resourcing, and a track record of building companies to successful exits.

He began his career in big pharma, organising Phase I trials across Europe, before setting up a bespoke clinical resourcing consultancy in the 1990s. He was a founding director of Cmed, a CRO later acquired by Aixial and now part of HiRO.

Mark then founded Clinicology, which he built over ten years before its acquisition by European CRO FGK Clinical Research, where he went on to serve as UK Managing Director.

His expertise spans clinical operations, contract talent and resourcing models, scaling service businesses and preparing them for sale. He now builds and invests in new ventures across clinical research and life sciences technology.

Stefan is a senior diagnostics and medical device professional with 12+ years’ experience spanning product development, technical support, customer services and operational leadership within ISO 13485 and FDA-regulated environments.

He has extensive experience developing and commercialising diagnostic technologies, most notably the Parsortix liquid biopsy platform, an FDA-cleared system for processing blood samples to capture circulating tumour cells. His experience covers product development from concept through verification and validation, regulatory submission, design transfer, commercialisation and lifecycle management.

Stefan has led multidisciplinary teams across R&D, engineering, biology, manufacturing and technical support, as well as building international customer support capabilities serving markets across North America, Europe, Asia-Pacific, the Middle East and Africa.

His expertise includes Design Control, risk management, complaint investigation, CAPA, root cause analysis, post-market surveillance, technical troubleshooting and continuous improvement. He combines strong scientific and technical expertise with a practical, customer-focused approach to problem solving and cross-functional leadership.

Most recently, Stefan led global technical support and services for diagnostic instrumentation and associated assays, managing customer escalations, technical investigations, field support and service operations. Previously, he led product and technology development activities contributing to FDA clearance of the Parsortix PC1 system and established an in-house manufacturing capability.

Stefan holds a PhD in Chemical and Biological Engineering from the University of Sheffield and a Diploma in Biotechnology from the University of Applied Sciences Weihenstephan, Germany.